Bevacizumab, the vascular endothelial growth factor-A (VEGF-A) monoclonal antibody, was the first proven target agent in the treatment of metastatic colorectal cancer (mCRC) and currently was a standard of care for mCRC patients in combination with first-line chemotherapy2, 3, 4. The gene discussed is VEGFA; the disease is metastatic colorectal cancer.